Choreo LLC Invests $324,000 in Privia Health Group, Inc. (NASDAQ:PRVA)

Choreo LLC acquired a new position in Privia Health Group, Inc. (NASDAQ:PRVA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 18,933 shares of the company’s stock, valued at approximately $324,000.

Other hedge funds also recently bought and sold shares of the company. Blair William & Co. IL raised its position in shares of Privia Health Group by 125.4% in the 1st quarter. Blair William & Co. IL now owns 51,564 shares of the company’s stock worth $1,010,000 after acquiring an additional 28,689 shares in the last quarter. Oppenheimer Asset Management Inc. raised its holdings in Privia Health Group by 27.1% in the first quarter. Oppenheimer Asset Management Inc. now owns 234,991 shares of the company’s stock worth $4,603,000 after purchasing an additional 50,042 shares in the last quarter. Peregrine Capital Management LLC lifted its position in shares of Privia Health Group by 11.5% during the second quarter. Peregrine Capital Management LLC now owns 314,190 shares of the company’s stock valued at $5,461,000 after buying an additional 32,311 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Privia Health Group by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 11,278,334 shares of the company’s stock valued at $259,740,000 after buying an additional 274,345 shares in the last quarter. Finally, FDx Advisors Inc. grew its position in shares of Privia Health Group by 71.6% in the 1st quarter. FDx Advisors Inc. now owns 20,067 shares of the company’s stock worth $393,000 after buying an additional 8,374 shares during the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Privia Health Group Price Performance

Shares of Privia Health Group stock opened at $18.80 on Wednesday. Privia Health Group, Inc. has a 1 year low of $15.92 and a 1 year high of $24.35. The stock has a market cap of $2.25 billion, a PE ratio of 125.33, a price-to-earnings-growth ratio of 4.40 and a beta of 0.77. The firm has a fifty day moving average price of $19.46 and a 200 day moving average price of $18.71.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.02). The company had revenue of $422.30 million during the quarter, compared to analyst estimates of $411.50 million. Privia Health Group had a net margin of 0.88% and a return on equity of 2.42%. The business’s quarterly revenue was up 2.2% compared to the same quarter last year. During the same period last year, the firm earned $0.06 EPS. As a group, equities analysts expect that Privia Health Group, Inc. will post 0.16 EPS for the current year.

Insider Transactions at Privia Health Group

In related news, CEO Parth Mehrotra sold 135,142 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $18.50, for a total transaction of $2,500,127.00. Following the sale, the chief executive officer now directly owns 247,771 shares of the company’s stock, valued at $4,583,763.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 14.20% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on PRVA. Robert W. Baird increased their price objective on Privia Health Group from $23.00 to $24.00 and gave the company an “outperform” rating in a report on Monday, August 26th. Baird R W raised Privia Health Group to a “strong-buy” rating in a report on Thursday, May 30th. Evercore ISI cut their price objective on shares of Privia Health Group from $23.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, July 9th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $28.00 target price on shares of Privia Health Group in a research note on Wednesday, August 14th. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.86.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.